nodes	percent_of_prediction	percent_of_DWPC	metapath
Lurasidone—CYP3A4—prostate cancer	0.22	1	CbGaD
Lurasidone—CYP3A4—Estradiol valerate/Dienogest—prostate cancer	0.072	0.207	CbGbCtD
Lurasidone—CYP3A4—Bicalutamide—prostate cancer	0.0378	0.109	CbGbCtD
Lurasidone—CYP3A4—Estramustine—prostate cancer	0.0352	0.101	CbGbCtD
Lurasidone—CYP3A4—Flutamide—prostate cancer	0.0313	0.09	CbGbCtD
Lurasidone—CYP3A4—Abiraterone—prostate cancer	0.0313	0.09	CbGbCtD
Lurasidone—CYP3A4—Cabazitaxel—prostate cancer	0.0232	0.0666	CbGbCtD
Lurasidone—CYP3A4—Estrone—prostate cancer	0.0227	0.0651	CbGbCtD
Lurasidone—HTR7—vas deferens—prostate cancer	0.0214	0.446	CbGeAlD
Lurasidone—CYP3A4—Ethinyl Estradiol—prostate cancer	0.0202	0.058	CbGbCtD
Lurasidone—CYP3A4—Conjugated Estrogens—prostate cancer	0.0148	0.0426	CbGbCtD
Lurasidone—CYP3A4—Mitoxantrone—prostate cancer	0.0135	0.0387	CbGbCtD
Lurasidone—CYP3A4—Estradiol—prostate cancer	0.013	0.0374	CbGbCtD
Lurasidone—CYP3A4—Prednisone—prostate cancer	0.0112	0.0321	CbGbCtD
Lurasidone—CYP3A4—Etoposide—prostate cancer	0.00849	0.0244	CbGbCtD
Lurasidone—CYP3A4—Docetaxel—prostate cancer	0.00777	0.0223	CbGbCtD
Lurasidone—CYP3A4—Doxorubicin—prostate cancer	0.00579	0.0166	CbGbCtD
Lurasidone—HTR2A—urine—prostate cancer	0.00332	0.0692	CbGeAlD
Lurasidone—CYP3A4—urine—prostate cancer	0.00308	0.064	CbGeAlD
Lurasidone—ADRA2C—prostate gland—prostate cancer	0.00176	0.0366	CbGeAlD
Lurasidone—ADRA2C—seminal vesicle—prostate cancer	0.00149	0.031	CbGeAlD
Lurasidone—HTR7—epithelium—prostate cancer	0.00141	0.0293	CbGeAlD
Lurasidone—ADRA2A—prostate gland—prostate cancer	0.0014	0.0292	CbGeAlD
Lurasidone—HTR1A—renal system—prostate cancer	0.00136	0.0284	CbGeAlD
Lurasidone—HTR7—renal system—prostate cancer	0.0013	0.0271	CbGeAlD
Lurasidone—ADRA2C—renal system—prostate cancer	0.0012	0.0249	CbGeAlD
Lurasidone—ADRA2A—seminal vesicle—prostate cancer	0.00119	0.0247	CbGeAlD
Lurasidone—ADRA2C—urethra—prostate cancer	0.00118	0.0245	CbGeAlD
Lurasidone—Ziprasidone—CYP3A5—prostate cancer	0.000981	0.698	CrCbGaD
Lurasidone—ADRA2A—urethra—prostate cancer	0.000939	0.0195	CbGeAlD
Lurasidone—HTR2A—epithelium—prostate cancer	0.000877	0.0182	CbGeAlD
Lurasidone—HTR7—testis—prostate cancer	0.000843	0.0175	CbGeAlD
Lurasidone—HTR2A—renal system—prostate cancer	0.000813	0.0169	CbGeAlD
Lurasidone—DRD2—testis—prostate cancer	0.000797	0.0166	CbGeAlD
Lurasidone—ADRA2C—testis—prostate cancer	0.000775	0.0161	CbGeAlD
Lurasidone—CYP3A4—renal system—prostate cancer	0.000753	0.0157	CbGeAlD
Lurasidone—ADRA2A—testis—prostate cancer	0.000618	0.0129	CbGeAlD
Lurasidone—ADRA2C—lymph node—prostate cancer	0.000562	0.0117	CbGeAlD
Lurasidone—HTR2A—testis—prostate cancer	0.000526	0.0109	CbGeAlD
Lurasidone—ADRA2A—lymph node—prostate cancer	0.000448	0.00932	CbGeAlD
Lurasidone—Ziprasidone—CYP3A4—prostate cancer	0.000425	0.302	CrCbGaD
Lurasidone—Weight increased—Epirubicin—prostate cancer	9.9e-05	0.000345	CcSEcCtD
Lurasidone—Loss of consciousness—Docetaxel—prostate cancer	9.88e-05	0.000344	CcSEcCtD
Lurasidone—Dyspnoea—Etoposide—prostate cancer	9.84e-05	0.000343	CcSEcCtD
Lurasidone—Hyperglycaemia—Epirubicin—prostate cancer	9.81e-05	0.000342	CcSEcCtD
Lurasidone—Malaise—Capecitabine—prostate cancer	9.81e-05	0.000342	CcSEcCtD
Lurasidone—Somnolence—Etoposide—prostate cancer	9.81e-05	0.000342	CcSEcCtD
Lurasidone—Angina pectoris—Doxorubicin—prostate cancer	9.8e-05	0.000342	CcSEcCtD
Lurasidone—Vertigo—Capecitabine—prostate cancer	9.77e-05	0.000341	CcSEcCtD
Lurasidone—Syncope—Capecitabine—prostate cancer	9.76e-05	0.00034	CcSEcCtD
Lurasidone—Mental disorder—Prednisone—prostate cancer	9.75e-05	0.00034	CcSEcCtD
Lurasidone—Diarrhoea—Estradiol—prostate cancer	9.74e-05	0.000339	CcSEcCtD
Lurasidone—Leukopenia—Capecitabine—prostate cancer	9.74e-05	0.000339	CcSEcCtD
Lurasidone—Convulsion—Docetaxel—prostate cancer	9.74e-05	0.000339	CcSEcCtD
Lurasidone—Hypertension—Docetaxel—prostate cancer	9.7e-05	0.000338	CcSEcCtD
Lurasidone—Infestation NOS—Epirubicin—prostate cancer	9.7e-05	0.000338	CcSEcCtD
Lurasidone—Infestation—Epirubicin—prostate cancer	9.7e-05	0.000338	CcSEcCtD
Lurasidone—Malnutrition—Prednisone—prostate cancer	9.69e-05	0.000338	CcSEcCtD
Lurasidone—Decreased appetite—Etoposide—prostate cancer	9.59e-05	0.000334	CcSEcCtD
Lurasidone—Myalgia—Docetaxel—prostate cancer	9.57e-05	0.000333	CcSEcCtD
Lurasidone—Loss of consciousness—Capecitabine—prostate cancer	9.56e-05	0.000333	CcSEcCtD
Lurasidone—Renal failure—Epirubicin—prostate cancer	9.53e-05	0.000332	CcSEcCtD
Lurasidone—Gastrointestinal disorder—Etoposide—prostate cancer	9.53e-05	0.000332	CcSEcCtD
Lurasidone—Asthenia—Mitoxantrone—prostate cancer	9.52e-05	0.000332	CcSEcCtD
Lurasidone—Fatigue—Etoposide—prostate cancer	9.51e-05	0.000331	CcSEcCtD
Lurasidone—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—prostate cancer	9.5e-05	0.000331	CcSEcCtD
Lurasidone—Urinary tract infection—Epirubicin—prostate cancer	9.43e-05	0.000328	CcSEcCtD
Lurasidone—Dizziness—Estradiol—prostate cancer	9.42e-05	0.000328	CcSEcCtD
Lurasidone—Dysuria—Doxorubicin—prostate cancer	9.41e-05	0.000328	CcSEcCtD
Lurasidone—Neutropenia—Doxorubicin—prostate cancer	9.41e-05	0.000328	CcSEcCtD
Lurasidone—Hypertension—Capecitabine—prostate cancer	9.39e-05	0.000327	CcSEcCtD
Lurasidone—Dry mouth—Docetaxel—prostate cancer	9.36e-05	0.000326	CcSEcCtD
Lurasidone—Myalgia—Capecitabine—prostate cancer	9.26e-05	0.000323	CcSEcCtD
Lurasidone—Anxiety—Capecitabine—prostate cancer	9.23e-05	0.000322	CcSEcCtD
Lurasidone—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—prostate cancer	9.2e-05	0.00032	CcSEcCtD
Lurasidone—Hepatobiliary disease—Epirubicin—prostate cancer	9.17e-05	0.00032	CcSEcCtD
Lurasidone—Weight increased—Doxorubicin—prostate cancer	9.16e-05	0.000319	CcSEcCtD
Lurasidone—Vision blurred—Prednisone—prostate cancer	9.13e-05	0.000318	CcSEcCtD
Lurasidone—Infection—Docetaxel—prostate cancer	9.11e-05	0.000317	CcSEcCtD
Lurasidone—Hyperglycaemia—Doxorubicin—prostate cancer	9.08e-05	0.000316	CcSEcCtD
Lurasidone—Diarrhoea—Mitoxantrone—prostate cancer	9.08e-05	0.000316	CcSEcCtD
Lurasidone—Dry mouth—Capecitabine—prostate cancer	9.06e-05	0.000316	CcSEcCtD
Lurasidone—Vomiting—Estradiol—prostate cancer	9.05e-05	0.000315	CcSEcCtD
Lurasidone—Agranulocytosis—Epirubicin—prostate cancer	9.05e-05	0.000315	CcSEcCtD
Lurasidone—Gastrointestinal pain—Etoposide—prostate cancer	9.02e-05	0.000314	CcSEcCtD
Lurasidone—Shock—Docetaxel—prostate cancer	9.02e-05	0.000314	CcSEcCtD
Lurasidone—Nervous system disorder—Docetaxel—prostate cancer	8.99e-05	0.000313	CcSEcCtD
Lurasidone—Rash—Estradiol—prostate cancer	8.98e-05	0.000313	CcSEcCtD
Lurasidone—Infestation NOS—Doxorubicin—prostate cancer	8.97e-05	0.000313	CcSEcCtD
Lurasidone—Infestation—Doxorubicin—prostate cancer	8.97e-05	0.000313	CcSEcCtD
Lurasidone—Dermatitis—Estradiol—prostate cancer	8.97e-05	0.000312	CcSEcCtD
Lurasidone—Anaemia—Prednisone—prostate cancer	8.96e-05	0.000312	CcSEcCtD
Lurasidone—Tachycardia—Docetaxel—prostate cancer	8.95e-05	0.000312	CcSEcCtD
Lurasidone—Skin disorder—Docetaxel—prostate cancer	8.91e-05	0.00031	CcSEcCtD
Lurasidone—Agitation—Prednisone—prostate cancer	8.91e-05	0.00031	CcSEcCtD
Lurasidone—Bradycardia—Epirubicin—prostate cancer	8.86e-05	0.000309	CcSEcCtD
Lurasidone—Angioedema—Prednisone—prostate cancer	8.86e-05	0.000309	CcSEcCtD
Lurasidone—Renal failure—Doxorubicin—prostate cancer	8.82e-05	0.000307	CcSEcCtD
Lurasidone—Infection—Capecitabine—prostate cancer	8.82e-05	0.000307	CcSEcCtD
Lurasidone—Malaise—Prednisone—prostate cancer	8.74e-05	0.000304	CcSEcCtD
Lurasidone—Shock—Capecitabine—prostate cancer	8.74e-05	0.000304	CcSEcCtD
Lurasidone—Abdominal pain—Etoposide—prostate cancer	8.72e-05	0.000304	CcSEcCtD
Lurasidone—Urinary tract infection—Doxorubicin—prostate cancer	8.72e-05	0.000304	CcSEcCtD
Lurasidone—Nervous system disorder—Capecitabine—prostate cancer	8.71e-05	0.000303	CcSEcCtD
Lurasidone—Vertigo—Prednisone—prostate cancer	8.71e-05	0.000303	CcSEcCtD
Lurasidone—Syncope—Prednisone—prostate cancer	8.69e-05	0.000303	CcSEcCtD
Lurasidone—Tachycardia—Capecitabine—prostate cancer	8.67e-05	0.000302	CcSEcCtD
Lurasidone—Skin disorder—Capecitabine—prostate cancer	8.62e-05	0.0003	CcSEcCtD
Lurasidone—Urinary tract disorder—Epirubicin—prostate cancer	8.6e-05	0.0003	CcSEcCtD
Lurasidone—Hyperhidrosis—Capecitabine—prostate cancer	8.58e-05	0.000299	CcSEcCtD
Lurasidone—Hypotension—Docetaxel—prostate cancer	8.57e-05	0.000299	CcSEcCtD
Lurasidone—Connective tissue disorder—Epirubicin—prostate cancer	8.56e-05	0.000298	CcSEcCtD
Lurasidone—Urethral disorder—Epirubicin—prostate cancer	8.54e-05	0.000297	CcSEcCtD
Lurasidone—Loss of consciousness—Prednisone—prostate cancer	8.52e-05	0.000297	CcSEcCtD
Lurasidone—Hepatobiliary disease—Doxorubicin—prostate cancer	8.49e-05	0.000296	CcSEcCtD
Lurasidone—Nausea—Estradiol—prostate cancer	8.46e-05	0.000295	CcSEcCtD
Lurasidone—Vomiting—Mitoxantrone—prostate cancer	8.44e-05	0.000294	CcSEcCtD
Lurasidone—Convulsion—Prednisone—prostate cancer	8.4e-05	0.000293	CcSEcCtD
Lurasidone—Agranulocytosis—Doxorubicin—prostate cancer	8.37e-05	0.000292	CcSEcCtD
Lurasidone—Hypertension—Prednisone—prostate cancer	8.37e-05	0.000291	CcSEcCtD
Lurasidone—Rash—Mitoxantrone—prostate cancer	8.37e-05	0.000291	CcSEcCtD
Lurasidone—Dermatitis—Mitoxantrone—prostate cancer	8.36e-05	0.000291	CcSEcCtD
Lurasidone—Musculoskeletal discomfort—Docetaxel—prostate cancer	8.36e-05	0.000291	CcSEcCtD
Lurasidone—Hypotension—Capecitabine—prostate cancer	8.3e-05	0.000289	CcSEcCtD
Lurasidone—Insomnia—Docetaxel—prostate cancer	8.29e-05	0.000289	CcSEcCtD
Lurasidone—Myalgia—Prednisone—prostate cancer	8.25e-05	0.000287	CcSEcCtD
Lurasidone—Anxiety—Prednisone—prostate cancer	8.22e-05	0.000286	CcSEcCtD
Lurasidone—Bradycardia—Doxorubicin—prostate cancer	8.2e-05	0.000286	CcSEcCtD
Lurasidone—Unspecified disorder of skin and subcutaneous tissue—Prednisone—prostate cancer	8.19e-05	0.000285	CcSEcCtD
Lurasidone—Dyspnoea—Docetaxel—prostate cancer	8.18e-05	0.000285	CcSEcCtD
Lurasidone—Somnolence—Docetaxel—prostate cancer	8.15e-05	0.000284	CcSEcCtD
Lurasidone—Eye disorder—Epirubicin—prostate cancer	8.14e-05	0.000283	CcSEcCtD
Lurasidone—Musculoskeletal discomfort—Capecitabine—prostate cancer	8.09e-05	0.000282	CcSEcCtD
Lurasidone—Cardiac disorder—Epirubicin—prostate cancer	8.08e-05	0.000282	CcSEcCtD
Lurasidone—Dyspepsia—Docetaxel—prostate cancer	8.07e-05	0.000281	CcSEcCtD
Lurasidone—Insomnia—Capecitabine—prostate cancer	8.03e-05	0.00028	CcSEcCtD
Lurasidone—Decreased appetite—Docetaxel—prostate cancer	7.97e-05	0.000278	CcSEcCtD
Lurasidone—Urinary tract disorder—Doxorubicin—prostate cancer	7.96e-05	0.000277	CcSEcCtD
Lurasidone—Gastrointestinal disorder—Docetaxel—prostate cancer	7.92e-05	0.000276	CcSEcCtD
Lurasidone—Asthenia—Etoposide—prostate cancer	7.92e-05	0.000276	CcSEcCtD
Lurasidone—Connective tissue disorder—Doxorubicin—prostate cancer	7.92e-05	0.000276	CcSEcCtD
Lurasidone—Dyspnoea—Capecitabine—prostate cancer	7.92e-05	0.000276	CcSEcCtD
Lurasidone—Fatigue—Docetaxel—prostate cancer	7.91e-05	0.000275	CcSEcCtD
Lurasidone—Angiopathy—Epirubicin—prostate cancer	7.9e-05	0.000275	CcSEcCtD
Lurasidone—Urethral disorder—Doxorubicin—prostate cancer	7.9e-05	0.000275	CcSEcCtD
Lurasidone—Nausea—Mitoxantrone—prostate cancer	7.88e-05	0.000275	CcSEcCtD
Lurasidone—Infection—Prednisone—prostate cancer	7.86e-05	0.000274	CcSEcCtD
Lurasidone—Dyspepsia—Capecitabine—prostate cancer	7.82e-05	0.000272	CcSEcCtD
Lurasidone—Pruritus—Etoposide—prostate cancer	7.81e-05	0.000272	CcSEcCtD
Lurasidone—Shock—Prednisone—prostate cancer	7.78e-05	0.000271	CcSEcCtD
Lurasidone—Arrhythmia—Epirubicin—prostate cancer	7.78e-05	0.000271	CcSEcCtD
Lurasidone—Nervous system disorder—Prednisone—prostate cancer	7.76e-05	0.00027	CcSEcCtD
Lurasidone—Tachycardia—Prednisone—prostate cancer	7.72e-05	0.000269	CcSEcCtD
Lurasidone—Decreased appetite—Capecitabine—prostate cancer	7.72e-05	0.000269	CcSEcCtD
Lurasidone—Skin disorder—Prednisone—prostate cancer	7.68e-05	0.000268	CcSEcCtD
Lurasidone—Gastrointestinal disorder—Capecitabine—prostate cancer	7.67e-05	0.000267	CcSEcCtD
Lurasidone—Fatigue—Capecitabine—prostate cancer	7.66e-05	0.000267	CcSEcCtD
Lurasidone—Hyperhidrosis—Prednisone—prostate cancer	7.65e-05	0.000266	CcSEcCtD
Lurasidone—Mental disorder—Epirubicin—prostate cancer	7.63e-05	0.000266	CcSEcCtD
Lurasidone—Malnutrition—Epirubicin—prostate cancer	7.58e-05	0.000264	CcSEcCtD
Lurasidone—Diarrhoea—Etoposide—prostate cancer	7.55e-05	0.000263	CcSEcCtD
Lurasidone—Eye disorder—Doxorubicin—prostate cancer	7.53e-05	0.000262	CcSEcCtD
Lurasidone—Gastrointestinal pain—Docetaxel—prostate cancer	7.5e-05	0.000261	CcSEcCtD
Lurasidone—Cardiac disorder—Doxorubicin—prostate cancer	7.48e-05	0.00026	CcSEcCtD
Lurasidone—Flatulence—Epirubicin—prostate cancer	7.47e-05	0.00026	CcSEcCtD
Lurasidone—Back pain—Epirubicin—prostate cancer	7.33e-05	0.000255	CcSEcCtD
Lurasidone—Angiopathy—Doxorubicin—prostate cancer	7.31e-05	0.000255	CcSEcCtD
Lurasidone—Dizziness—Etoposide—prostate cancer	7.3e-05	0.000254	CcSEcCtD
Lurasidone—Muscle spasms—Epirubicin—prostate cancer	7.29e-05	0.000254	CcSEcCtD
Lurasidone—Gastrointestinal pain—Capecitabine—prostate cancer	7.26e-05	0.000253	CcSEcCtD
Lurasidone—Abdominal pain—Docetaxel—prostate cancer	7.25e-05	0.000253	CcSEcCtD
Lurasidone—Musculoskeletal discomfort—Prednisone—prostate cancer	7.21e-05	0.000251	CcSEcCtD
Lurasidone—Arrhythmia—Doxorubicin—prostate cancer	7.2e-05	0.000251	CcSEcCtD
Lurasidone—Insomnia—Prednisone—prostate cancer	7.15e-05	0.000249	CcSEcCtD
Lurasidone—Vision blurred—Epirubicin—prostate cancer	7.14e-05	0.000249	CcSEcCtD
Lurasidone—Mental disorder—Doxorubicin—prostate cancer	7.06e-05	0.000246	CcSEcCtD
Lurasidone—Abdominal pain—Capecitabine—prostate cancer	7.02e-05	0.000245	CcSEcCtD
Lurasidone—Vomiting—Etoposide—prostate cancer	7.02e-05	0.000244	CcSEcCtD
Lurasidone—Malnutrition—Doxorubicin—prostate cancer	7.01e-05	0.000244	CcSEcCtD
Lurasidone—Anaemia—Epirubicin—prostate cancer	7.01e-05	0.000244	CcSEcCtD
Lurasidone—Agitation—Epirubicin—prostate cancer	6.97e-05	0.000243	CcSEcCtD
Lurasidone—Dyspepsia—Prednisone—prostate cancer	6.96e-05	0.000243	CcSEcCtD
Lurasidone—Rash—Etoposide—prostate cancer	6.96e-05	0.000242	CcSEcCtD
Lurasidone—Dermatitis—Etoposide—prostate cancer	6.95e-05	0.000242	CcSEcCtD
Lurasidone—Flatulence—Doxorubicin—prostate cancer	6.91e-05	0.000241	CcSEcCtD
Lurasidone—Decreased appetite—Prednisone—prostate cancer	6.88e-05	0.00024	CcSEcCtD
Lurasidone—Malaise—Epirubicin—prostate cancer	6.84e-05	0.000238	CcSEcCtD
Lurasidone—Fatigue—Prednisone—prostate cancer	6.82e-05	0.000238	CcSEcCtD
Lurasidone—Vertigo—Epirubicin—prostate cancer	6.81e-05	0.000237	CcSEcCtD
Lurasidone—Syncope—Epirubicin—prostate cancer	6.8e-05	0.000237	CcSEcCtD
Lurasidone—Leukopenia—Epirubicin—prostate cancer	6.78e-05	0.000236	CcSEcCtD
Lurasidone—Back pain—Doxorubicin—prostate cancer	6.78e-05	0.000236	CcSEcCtD
Lurasidone—Muscle spasms—Doxorubicin—prostate cancer	6.74e-05	0.000235	CcSEcCtD
Lurasidone—Loss of consciousness—Epirubicin—prostate cancer	6.66e-05	0.000232	CcSEcCtD
Lurasidone—Vision blurred—Doxorubicin—prostate cancer	6.61e-05	0.00023	CcSEcCtD
Lurasidone—Asthenia—Docetaxel—prostate cancer	6.58e-05	0.000229	CcSEcCtD
Lurasidone—Convulsion—Epirubicin—prostate cancer	6.57e-05	0.000229	CcSEcCtD
Lurasidone—Nausea—Etoposide—prostate cancer	6.55e-05	0.000228	CcSEcCtD
Lurasidone—Hypertension—Epirubicin—prostate cancer	6.54e-05	0.000228	CcSEcCtD
Lurasidone—Pruritus—Docetaxel—prostate cancer	6.49e-05	0.000226	CcSEcCtD
Lurasidone—Anaemia—Doxorubicin—prostate cancer	6.48e-05	0.000226	CcSEcCtD
Lurasidone—Gastrointestinal pain—Prednisone—prostate cancer	6.47e-05	0.000225	CcSEcCtD
Lurasidone—Myalgia—Epirubicin—prostate cancer	6.45e-05	0.000225	CcSEcCtD
Lurasidone—Agitation—Doxorubicin—prostate cancer	6.44e-05	0.000225	CcSEcCtD
Lurasidone—Anxiety—Epirubicin—prostate cancer	6.43e-05	0.000224	CcSEcCtD
Lurasidone—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—prostate cancer	6.41e-05	0.000223	CcSEcCtD
Lurasidone—Asthenia—Capecitabine—prostate cancer	6.37e-05	0.000222	CcSEcCtD
Lurasidone—Malaise—Doxorubicin—prostate cancer	6.32e-05	0.00022	CcSEcCtD
Lurasidone—Dry mouth—Epirubicin—prostate cancer	6.31e-05	0.00022	CcSEcCtD
Lurasidone—Vertigo—Doxorubicin—prostate cancer	6.3e-05	0.00022	CcSEcCtD
Lurasidone—Syncope—Doxorubicin—prostate cancer	6.29e-05	0.000219	CcSEcCtD
Lurasidone—Pruritus—Capecitabine—prostate cancer	6.28e-05	0.000219	CcSEcCtD
Lurasidone—Leukopenia—Doxorubicin—prostate cancer	6.28e-05	0.000219	CcSEcCtD
Lurasidone—Diarrhoea—Docetaxel—prostate cancer	6.28e-05	0.000219	CcSEcCtD
Lurasidone—Abdominal pain—Prednisone—prostate cancer	6.25e-05	0.000218	CcSEcCtD
Lurasidone—Loss of consciousness—Doxorubicin—prostate cancer	6.16e-05	0.000215	CcSEcCtD
Lurasidone—Infection—Epirubicin—prostate cancer	6.15e-05	0.000214	CcSEcCtD
Lurasidone—Shock—Epirubicin—prostate cancer	6.09e-05	0.000212	CcSEcCtD
Lurasidone—Convulsion—Doxorubicin—prostate cancer	6.08e-05	0.000212	CcSEcCtD
Lurasidone—Diarrhoea—Capecitabine—prostate cancer	6.08e-05	0.000212	CcSEcCtD
Lurasidone—Nervous system disorder—Epirubicin—prostate cancer	6.07e-05	0.000211	CcSEcCtD
Lurasidone—Dizziness—Docetaxel—prostate cancer	6.06e-05	0.000211	CcSEcCtD
Lurasidone—Hypertension—Doxorubicin—prostate cancer	6.05e-05	0.000211	CcSEcCtD
Lurasidone—Tachycardia—Epirubicin—prostate cancer	6.04e-05	0.00021	CcSEcCtD
Lurasidone—Skin disorder—Epirubicin—prostate cancer	6.01e-05	0.000209	CcSEcCtD
Lurasidone—Hyperhidrosis—Epirubicin—prostate cancer	5.98e-05	0.000208	CcSEcCtD
Lurasidone—Myalgia—Doxorubicin—prostate cancer	5.97e-05	0.000208	CcSEcCtD
Lurasidone—Anxiety—Doxorubicin—prostate cancer	5.95e-05	0.000207	CcSEcCtD
Lurasidone—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—prostate cancer	5.93e-05	0.000207	CcSEcCtD
Lurasidone—Dizziness—Capecitabine—prostate cancer	5.87e-05	0.000205	CcSEcCtD
Lurasidone—Dry mouth—Doxorubicin—prostate cancer	5.84e-05	0.000203	CcSEcCtD
Lurasidone—Vomiting—Docetaxel—prostate cancer	5.83e-05	0.000203	CcSEcCtD
Lurasidone—Rash—Docetaxel—prostate cancer	5.78e-05	0.000201	CcSEcCtD
Lurasidone—Hypotension—Epirubicin—prostate cancer	5.78e-05	0.000201	CcSEcCtD
Lurasidone—Dermatitis—Docetaxel—prostate cancer	5.78e-05	0.000201	CcSEcCtD
Lurasidone—Infection—Doxorubicin—prostate cancer	5.69e-05	0.000198	CcSEcCtD
Lurasidone—Asthenia—Prednisone—prostate cancer	5.67e-05	0.000198	CcSEcCtD
Lurasidone—Vomiting—Capecitabine—prostate cancer	5.65e-05	0.000197	CcSEcCtD
Lurasidone—Musculoskeletal discomfort—Epirubicin—prostate cancer	5.64e-05	0.000196	CcSEcCtD
Lurasidone—Shock—Doxorubicin—prostate cancer	5.63e-05	0.000196	CcSEcCtD
Lurasidone—Nervous system disorder—Doxorubicin—prostate cancer	5.61e-05	0.000196	CcSEcCtD
Lurasidone—Rash—Capecitabine—prostate cancer	5.6e-05	0.000195	CcSEcCtD
Lurasidone—Pruritus—Prednisone—prostate cancer	5.6e-05	0.000195	CcSEcCtD
Lurasidone—Insomnia—Epirubicin—prostate cancer	5.59e-05	0.000195	CcSEcCtD
Lurasidone—Dermatitis—Capecitabine—prostate cancer	5.59e-05	0.000195	CcSEcCtD
Lurasidone—Tachycardia—Doxorubicin—prostate cancer	5.59e-05	0.000195	CcSEcCtD
Lurasidone—Skin disorder—Doxorubicin—prostate cancer	5.56e-05	0.000194	CcSEcCtD
Lurasidone—Hyperhidrosis—Doxorubicin—prostate cancer	5.53e-05	0.000193	CcSEcCtD
Lurasidone—Dyspnoea—Epirubicin—prostate cancer	5.52e-05	0.000192	CcSEcCtD
Lurasidone—Somnolence—Epirubicin—prostate cancer	5.5e-05	0.000192	CcSEcCtD
Lurasidone—Nausea—Docetaxel—prostate cancer	5.45e-05	0.00019	CcSEcCtD
Lurasidone—Dyspepsia—Epirubicin—prostate cancer	5.45e-05	0.00019	CcSEcCtD
Lurasidone—Diarrhoea—Prednisone—prostate cancer	5.41e-05	0.000189	CcSEcCtD
Lurasidone—Decreased appetite—Epirubicin—prostate cancer	5.38e-05	0.000187	CcSEcCtD
Lurasidone—Hypotension—Doxorubicin—prostate cancer	5.35e-05	0.000186	CcSEcCtD
Lurasidone—Gastrointestinal disorder—Epirubicin—prostate cancer	5.34e-05	0.000186	CcSEcCtD
Lurasidone—Fatigue—Epirubicin—prostate cancer	5.33e-05	0.000186	CcSEcCtD
Lurasidone—Nausea—Capecitabine—prostate cancer	5.27e-05	0.000184	CcSEcCtD
Lurasidone—Dizziness—Prednisone—prostate cancer	5.23e-05	0.000182	CcSEcCtD
Lurasidone—Musculoskeletal discomfort—Doxorubicin—prostate cancer	5.21e-05	0.000182	CcSEcCtD
Lurasidone—Insomnia—Doxorubicin—prostate cancer	5.18e-05	0.00018	CcSEcCtD
Lurasidone—Dyspnoea—Doxorubicin—prostate cancer	5.1e-05	0.000178	CcSEcCtD
Lurasidone—Somnolence—Doxorubicin—prostate cancer	5.09e-05	0.000177	CcSEcCtD
Lurasidone—Gastrointestinal pain—Epirubicin—prostate cancer	5.06e-05	0.000176	CcSEcCtD
Lurasidone—Dyspepsia—Doxorubicin—prostate cancer	5.04e-05	0.000176	CcSEcCtD
Lurasidone—Vomiting—Prednisone—prostate cancer	5.03e-05	0.000175	CcSEcCtD
Lurasidone—Rash—Prednisone—prostate cancer	4.99e-05	0.000174	CcSEcCtD
Lurasidone—Dermatitis—Prednisone—prostate cancer	4.98e-05	0.000174	CcSEcCtD
Lurasidone—Decreased appetite—Doxorubicin—prostate cancer	4.98e-05	0.000173	CcSEcCtD
Lurasidone—Gastrointestinal disorder—Doxorubicin—prostate cancer	4.94e-05	0.000172	CcSEcCtD
Lurasidone—Fatigue—Doxorubicin—prostate cancer	4.93e-05	0.000172	CcSEcCtD
Lurasidone—Abdominal pain—Epirubicin—prostate cancer	4.89e-05	0.00017	CcSEcCtD
Lurasidone—Nausea—Prednisone—prostate cancer	4.7e-05	0.000164	CcSEcCtD
Lurasidone—Gastrointestinal pain—Doxorubicin—prostate cancer	4.68e-05	0.000163	CcSEcCtD
Lurasidone—Abdominal pain—Doxorubicin—prostate cancer	4.52e-05	0.000158	CcSEcCtD
Lurasidone—Asthenia—Epirubicin—prostate cancer	4.44e-05	0.000155	CcSEcCtD
Lurasidone—Pruritus—Epirubicin—prostate cancer	4.38e-05	0.000152	CcSEcCtD
Lurasidone—Diarrhoea—Epirubicin—prostate cancer	4.23e-05	0.000147	CcSEcCtD
Lurasidone—Asthenia—Doxorubicin—prostate cancer	4.11e-05	0.000143	CcSEcCtD
Lurasidone—Dizziness—Epirubicin—prostate cancer	4.09e-05	0.000143	CcSEcCtD
Lurasidone—Pruritus—Doxorubicin—prostate cancer	4.05e-05	0.000141	CcSEcCtD
Lurasidone—Vomiting—Epirubicin—prostate cancer	3.93e-05	0.000137	CcSEcCtD
Lurasidone—Diarrhoea—Doxorubicin—prostate cancer	3.92e-05	0.000136	CcSEcCtD
Lurasidone—Rash—Epirubicin—prostate cancer	3.9e-05	0.000136	CcSEcCtD
Lurasidone—Dermatitis—Epirubicin—prostate cancer	3.9e-05	0.000136	CcSEcCtD
Lurasidone—Dizziness—Doxorubicin—prostate cancer	3.78e-05	0.000132	CcSEcCtD
Lurasidone—Nausea—Epirubicin—prostate cancer	3.67e-05	0.000128	CcSEcCtD
Lurasidone—Vomiting—Doxorubicin—prostate cancer	3.64e-05	0.000127	CcSEcCtD
Lurasidone—Rash—Doxorubicin—prostate cancer	3.61e-05	0.000126	CcSEcCtD
Lurasidone—Dermatitis—Doxorubicin—prostate cancer	3.61e-05	0.000126	CcSEcCtD
Lurasidone—Nausea—Doxorubicin—prostate cancer	3.4e-05	0.000118	CcSEcCtD
Lurasidone—ADRA2C—Signaling Pathways—SERPINE1—prostate cancer	5.93e-06	6.23e-05	CbGpPWpGaD
Lurasidone—CYP3A4—Metabolism—CYP2A6—prostate cancer	5.9e-06	6.2e-05	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling by GPCR—KRAS—prostate cancer	5.87e-06	6.17e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—ESR1—prostate cancer	5.86e-06	6.16e-05	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—INS—prostate cancer	5.86e-06	6.16e-05	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—NOS3—prostate cancer	5.85e-06	6.15e-05	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—GSK3B—prostate cancer	5.85e-06	6.14e-05	CbGpPWpGaD
Lurasidone—HTR7—Signaling Pathways—SRC—prostate cancer	5.84e-06	6.14e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Metabolism—PIK3CD—prostate cancer	5.83e-06	6.12e-05	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—INS—prostate cancer	5.77e-06	6.06e-05	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—FGF2—prostate cancer	5.74e-06	6.03e-05	CbGpPWpGaD
Lurasidone—CYP3A4—Metabolism—AKR1C3—prostate cancer	5.74e-06	6.03e-05	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—CREBBP—prostate cancer	5.74e-06	6.03e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—BAD—prostate cancer	5.72e-06	6.01e-05	CbGpPWpGaD
Lurasidone—CYP3A4—Metabolism—PRKACB—prostate cancer	5.71e-06	6e-05	CbGpPWpGaD
Lurasidone—HTR7—Signaling Pathways—VEGFA—prostate cancer	5.69e-06	5.98e-05	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—JAK2—prostate cancer	5.69e-06	5.98e-05	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—IGF1—prostate cancer	5.67e-06	5.96e-05	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—NOS3—prostate cancer	5.66e-06	5.95e-05	CbGpPWpGaD
Lurasidone—CYP3A4—Metabolism—CYP17A1—prostate cancer	5.65e-06	5.94e-05	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—CREBBP—prostate cancer	5.65e-06	5.93e-05	CbGpPWpGaD
Lurasidone—DRD2—Signaling by GPCR—EGFR—prostate cancer	5.64e-06	5.93e-05	CbGpPWpGaD
Lurasidone—HTR7—Signaling Pathways—STAT3—prostate cancer	5.63e-06	5.92e-05	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—IGF1—prostate cancer	5.58e-06	5.86e-05	CbGpPWpGaD
Lurasidone—HTR1A—Signaling by GPCR—PIK3CA—prostate cancer	5.58e-06	5.86e-05	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—MDM2—prostate cancer	5.55e-06	5.83e-05	CbGpPWpGaD
Lurasidone—HTR2A—Signaling by GPCR—EGFR—prostate cancer	5.55e-06	5.83e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—APC—prostate cancer	5.54e-06	5.82e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—PIK3CG—prostate cancer	5.54e-06	5.82e-05	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—JAK2—prostate cancer	5.5e-06	5.78e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Metabolism—NOS3—prostate cancer	5.5e-06	5.78e-05	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—MAP2K1—prostate cancer	5.48e-06	5.76e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—IRS1—prostate cancer	5.48e-06	5.76e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—EGF—prostate cancer	5.48e-06	5.76e-05	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—ERBB2—prostate cancer	5.48e-06	5.75e-05	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—PIK3CD—prostate cancer	5.44e-06	5.72e-05	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—PIK3CB—prostate cancer	5.4e-06	5.68e-05	CbGpPWpGaD
Lurasidone—ADRA2C—Metabolism—PTEN—prostate cancer	5.4e-06	5.68e-05	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling by GPCR—PIK3CA—prostate cancer	5.4e-06	5.67e-05	CbGpPWpGaD
Lurasidone—DRD2—GPCR downstream signaling—PIK3CA—prostate cancer	5.39e-06	5.66e-05	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—MAP2K1—prostate cancer	5.39e-06	5.66e-05	CbGpPWpGaD
Lurasidone—CYP3A4—Metabolism—NCOA2—prostate cancer	5.39e-06	5.66e-05	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—SERPINE1—prostate cancer	5.38e-06	5.66e-05	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—MDM2—prostate cancer	5.37e-06	5.65e-05	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—PIK3CD—prostate cancer	5.36e-06	5.63e-05	CbGpPWpGaD
Lurasidone—DRD2—Signaling by GPCR—KRAS—prostate cancer	5.33e-06	5.6e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—GSK3B—prostate cancer	5.32e-06	5.59e-05	CbGpPWpGaD
Lurasidone—HTR2A—GPCR downstream signaling—PIK3CA—prostate cancer	5.3e-06	5.57e-05	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—ERBB2—prostate cancer	5.3e-06	5.57e-05	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—SERPINE1—prostate cancer	5.3e-06	5.56e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—INS—prostate cancer	5.25e-06	5.51e-05	CbGpPWpGaD
Lurasidone—HTR2A—Signaling by GPCR—KRAS—prostate cancer	5.24e-06	5.51e-05	CbGpPWpGaD
Lurasidone—HTR7—Signaling Pathways—MYC—prostate cancer	5.24e-06	5.5e-05	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—PIK3CB—prostate cancer	5.23e-06	5.49e-05	CbGpPWpGaD
Lurasidone—HTR7—Signaling Pathways—TGFB1—prostate cancer	5.22e-06	5.49e-05	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—FGF2—prostate cancer	5.21e-06	5.47e-05	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—CXCL8—prostate cancer	5.19e-06	5.46e-05	CbGpPWpGaD
Lurasidone—ADRA2C—Metabolism—EP300—prostate cancer	5.15e-06	5.41e-05	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—NOS3—prostate cancer	5.14e-06	5.4e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—CREBBP—prostate cancer	5.14e-06	5.4e-05	CbGpPWpGaD
Lurasidone—CYP3A4—Metabolism—SLC5A5—prostate cancer	5.14e-06	5.4e-05	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—FGF2—prostate cancer	5.13e-06	5.39e-05	CbGpPWpGaD
Lurasidone—HTR7—Signaling Pathways—EGFR—prostate cancer	5.12e-06	5.38e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Metabolism—PIK3CB—prostate cancer	5.08e-06	5.34e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—IGF1—prostate cancer	5.07e-06	5.33e-05	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—CDKN1B—prostate cancer	5.07e-06	5.33e-05	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—NOS3—prostate cancer	5.06e-06	5.31e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling by GPCR—EGFR—prostate cancer	5.05e-06	5.3e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Metabolism—PTGS2—prostate cancer	5.03e-06	5.29e-05	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—CXCL8—prostate cancer	5.02e-06	5.28e-05	CbGpPWpGaD
Lurasidone—CYP3A4—Metabolism—CYP2E1—prostate cancer	5.02e-06	5.27e-05	CbGpPWpGaD
Lurasidone—HTR1A—GPCR downstream signaling—AKT1—prostate cancer	5.02e-06	5.27e-05	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—JAK2—prostate cancer	4.99e-06	5.25e-05	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—CASP3—prostate cancer	4.97e-06	5.22e-05	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—IL2—prostate cancer	4.96e-06	5.21e-05	CbGpPWpGaD
Lurasidone—CYP3A4—Metabolism—NQO1—prostate cancer	4.96e-06	5.21e-05	CbGpPWpGaD
Lurasidone—HTR1A—Signaling by GPCR—IL6—prostate cancer	4.94e-06	5.19e-05	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—JAK2—prostate cancer	4.91e-06	5.16e-05	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—CDKN1B—prostate cancer	4.91e-06	5.15e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—MAP2K1—prostate cancer	4.9e-06	5.15e-05	CbGpPWpGaD
Lurasidone—DRD2—Signaling by GPCR—PIK3CA—prostate cancer	4.9e-06	5.14e-05	CbGpPWpGaD
Lurasidone—CYP3A4—Metabolism—TH—prostate cancer	4.89e-06	5.14e-05	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—MDM2—prostate cancer	4.88e-06	5.12e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—PIK3CD—prostate cancer	4.87e-06	5.12e-05	CbGpPWpGaD
Lurasidone—ADRA2C—GPCR downstream signaling—AKT1—prostate cancer	4.85e-06	5.1e-05	CbGpPWpGaD
Lurasidone—HTR7—Signaling Pathways—KRAS—prostate cancer	4.84e-06	5.08e-05	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—CCND1—prostate cancer	4.84e-06	5.08e-05	CbGpPWpGaD
Lurasidone—ADRA2A—GPCR downstream signaling—PIK3CA—prostate cancer	4.83e-06	5.07e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—SERPINE1—prostate cancer	4.82e-06	5.06e-05	CbGpPWpGaD
Lurasidone—HTR2A—Signaling by GPCR—PIK3CA—prostate cancer	4.82e-06	5.06e-05	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—CASP3—prostate cancer	4.81e-06	5.05e-05	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—ERBB2—prostate cancer	4.81e-06	5.05e-05	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—IL2—prostate cancer	4.8e-06	5.04e-05	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—MDM2—prostate cancer	4.8e-06	5.04e-05	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—CTNNB1—prostate cancer	4.79e-06	5.03e-05	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling by GPCR—IL6—prostate cancer	4.78e-06	5.02e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling by GPCR—KRAS—prostate cancer	4.77e-06	5.01e-05	CbGpPWpGaD
Lurasidone—CYP3A4—Metabolism—CYP1B1—prostate cancer	4.76e-06	5e-05	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—PIK3CB—prostate cancer	4.74e-06	4.98e-05	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—ERBB2—prostate cancer	4.73e-06	4.97e-05	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—MMP9—prostate cancer	4.7e-06	4.93e-05	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—CCND1—prostate cancer	4.68e-06	4.92e-05	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—CDKN1A—prostate cancer	4.68e-06	4.92e-05	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—PTEN—prostate cancer	4.67e-06	4.91e-05	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—PIK3CB—prostate cancer	4.67e-06	4.9e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—FGF2—prostate cancer	4.66e-06	4.9e-05	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—CTNNB1—prostate cancer	4.64e-06	4.87e-05	CbGpPWpGaD
Lurasidone—CYP3A4—Metabolism—GGT1—prostate cancer	4.61e-06	4.84e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—NOS3—prostate cancer	4.6e-06	4.83e-05	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—CXCL8—prostate cancer	4.56e-06	4.79e-05	CbGpPWpGaD
Lurasidone—HTR1A—Signaling by GPCR—AKT1—prostate cancer	4.55e-06	4.79e-05	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—MMP9—prostate cancer	4.54e-06	4.77e-05	CbGpPWpGaD
Lurasidone—CYP3A4—Metabolism—NCOA1—prostate cancer	4.54e-06	4.77e-05	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—CDKN1A—prostate cancer	4.53e-06	4.76e-05	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—PTEN—prostate cancer	4.52e-06	4.75e-05	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—CXCL8—prostate cancer	4.49e-06	4.71e-05	CbGpPWpGaD
Lurasidone—CYP3A4—Metabolism—CYP19A1—prostate cancer	4.47e-06	4.7e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—JAK2—prostate cancer	4.47e-06	4.7e-05	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—EP300—prostate cancer	4.45e-06	4.68e-05	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—CDKN1B—prostate cancer	4.45e-06	4.68e-05	CbGpPWpGaD
Lurasidone—HTR7—Signaling Pathways—PIK3CA—prostate cancer	4.44e-06	4.67e-05	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling by GPCR—AKT1—prostate cancer	4.41e-06	4.63e-05	CbGpPWpGaD
Lurasidone—DRD2—GPCR downstream signaling—AKT1—prostate cancer	4.4e-06	4.63e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Metabolism—PTEN—prostate cancer	4.39e-06	4.61e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling by GPCR—PIK3CA—prostate cancer	4.38e-06	4.6e-05	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—CDKN1B—prostate cancer	4.38e-06	4.6e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—MDM2—prostate cancer	4.36e-06	4.59e-05	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—CASP3—prostate cancer	4.36e-06	4.58e-05	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—IL2—prostate cancer	4.36e-06	4.58e-05	CbGpPWpGaD
Lurasidone—DRD2—Signaling by GPCR—IL6—prostate cancer	4.33e-06	4.55e-05	CbGpPWpGaD
Lurasidone—HTR2A—GPCR downstream signaling—AKT1—prostate cancer	4.33e-06	4.55e-05	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—SRC—prostate cancer	4.33e-06	4.55e-05	CbGpPWpGaD
Lurasidone—CYP3A4—Metabolism—RXRA—prostate cancer	4.32e-06	4.53e-05	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—EP300—prostate cancer	4.31e-06	4.53e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—ERBB2—prostate cancer	4.3e-06	4.52e-05	CbGpPWpGaD
Lurasidone—HTR7—Signaling Pathways—TP53—prostate cancer	4.3e-06	4.52e-05	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—CASP3—prostate cancer	4.29e-06	4.51e-05	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—IL2—prostate cancer	4.29e-06	4.5e-05	CbGpPWpGaD
Lurasidone—HTR2A—Signaling by GPCR—IL6—prostate cancer	4.27e-06	4.48e-05	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—CCND1—prostate cancer	4.25e-06	4.46e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—PIK3CB—prostate cancer	4.25e-06	4.46e-05	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—VEGFA—prostate cancer	4.22e-06	4.43e-05	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—CTNNB1—prostate cancer	4.21e-06	4.42e-05	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—SRC—prostate cancer	4.19e-06	4.4e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Metabolism—EP300—prostate cancer	4.19e-06	4.4e-05	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—CCND1—prostate cancer	4.18e-06	4.39e-05	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—STAT3—prostate cancer	4.18e-06	4.39e-05	CbGpPWpGaD
Lurasidone—CYP3A4—Metabolism—COMT—prostate cancer	4.16e-06	4.37e-05	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—CTNNB1—prostate cancer	4.14e-06	4.35e-05	CbGpPWpGaD
Lurasidone—CYP3A4—Metabolism—GSTP1—prostate cancer	4.14e-06	4.35e-05	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—MMP9—prostate cancer	4.12e-06	4.33e-05	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—CDKN1A—prostate cancer	4.11e-06	4.32e-05	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—PTEN—prostate cancer	4.1e-06	4.31e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—CXCL8—prostate cancer	4.08e-06	4.29e-05	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—VEGFA—prostate cancer	4.08e-06	4.29e-05	CbGpPWpGaD
Lurasidone—CYP3A4—Metabolism—ITPR1—prostate cancer	4.07e-06	4.28e-05	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—MMP9—prostate cancer	4.06e-06	4.26e-05	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—CDKN1A—prostate cancer	4.04e-06	4.25e-05	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—STAT3—prostate cancer	4.04e-06	4.25e-05	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—PTEN—prostate cancer	4.03e-06	4.24e-05	CbGpPWpGaD
Lurasidone—DRD2—Signaling by GPCR—AKT1—prostate cancer	4e-06	4.2e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—CDKN1B—prostate cancer	3.99e-06	4.19e-05	CbGpPWpGaD
Lurasidone—ADRA2A—GPCR downstream signaling—AKT1—prostate cancer	3.94e-06	4.14e-05	CbGpPWpGaD
Lurasidone—HTR7—Signaling Pathways—IL6—prostate cancer	3.94e-06	4.14e-05	CbGpPWpGaD
Lurasidone—HTR2A—Signaling by GPCR—AKT1—prostate cancer	3.94e-06	4.13e-05	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—EP300—prostate cancer	3.91e-06	4.11e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—CASP3—prostate cancer	3.91e-06	4.1e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—IL2—prostate cancer	3.9e-06	4.1e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling by GPCR—IL6—prostate cancer	3.88e-06	4.08e-05	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—MYC—prostate cancer	3.88e-06	4.08e-05	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—TGFB1—prostate cancer	3.87e-06	4.07e-05	CbGpPWpGaD
Lurasidone—CYP3A4—Metabolism—TYMS—prostate cancer	3.85e-06	4.04e-05	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—EP300—prostate cancer	3.85e-06	4.04e-05	CbGpPWpGaD
Lurasidone—ADRA2C—Metabolism—PIK3CA—prostate cancer	3.81e-06	4e-05	CbGpPWpGaD
Lurasidone—CYP3A4—Metabolism—GSTM1—prostate cancer	3.8e-06	4e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—CCND1—prostate cancer	3.8e-06	3.99e-05	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—SRC—prostate cancer	3.8e-06	3.99e-05	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—EGFR—prostate cancer	3.8e-06	3.99e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—CTNNB1—prostate cancer	3.76e-06	3.96e-05	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—MYC—prostate cancer	3.75e-06	3.94e-05	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—TGFB1—prostate cancer	3.75e-06	3.93e-05	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—SRC—prostate cancer	3.74e-06	3.93e-05	CbGpPWpGaD
Lurasidone—CYP3A4—Metabolism—LPL—prostate cancer	3.73e-06	3.92e-05	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—VEGFA—prostate cancer	3.7e-06	3.89e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—MMP9—prostate cancer	3.69e-06	3.88e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—CDKN1A—prostate cancer	3.68e-06	3.86e-05	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—EGFR—prostate cancer	3.67e-06	3.86e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—PTEN—prostate cancer	3.67e-06	3.86e-05	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—STAT3—prostate cancer	3.67e-06	3.85e-05	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—VEGFA—prostate cancer	3.64e-06	3.83e-05	CbGpPWpGaD
Lurasidone—HTR7—Signaling Pathways—AKT1—prostate cancer	3.63e-06	3.81e-05	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—STAT3—prostate cancer	3.61e-06	3.79e-05	CbGpPWpGaD
Lurasidone—CYP3A4—Metabolism—CYP1A1—prostate cancer	3.61e-06	3.79e-05	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—KRAS—prostate cancer	3.59e-06	3.77e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling by GPCR—AKT1—prostate cancer	3.58e-06	3.76e-05	CbGpPWpGaD
Lurasidone—CYP3A4—Metabolism—ERCC2—prostate cancer	3.58e-06	3.76e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—EP300—prostate cancer	3.5e-06	3.68e-05	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—KRAS—prostate cancer	3.47e-06	3.64e-05	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—MYC—prostate cancer	3.41e-06	3.58e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—SRC—prostate cancer	3.4e-06	3.58e-05	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—TGFB1—prostate cancer	3.4e-06	3.57e-05	CbGpPWpGaD
Lurasidone—CYP3A4—Metabolism—MTHFR—prostate cancer	3.36e-06	3.53e-05	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—MYC—prostate cancer	3.35e-06	3.52e-05	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—TGFB1—prostate cancer	3.34e-06	3.51e-05	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—EGFR—prostate cancer	3.33e-06	3.5e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—VEGFA—prostate cancer	3.31e-06	3.48e-05	CbGpPWpGaD
Lurasidone—CYP3A4—Metabolism—PPARA—prostate cancer	3.3e-06	3.46e-05	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—PIK3CA—prostate cancer	3.29e-06	3.46e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—STAT3—prostate cancer	3.28e-06	3.45e-05	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—EGFR—prostate cancer	3.28e-06	3.44e-05	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—PIK3CA—prostate cancer	3.19e-06	3.35e-05	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—TP53—prostate cancer	3.19e-06	3.35e-05	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—KRAS—prostate cancer	3.15e-06	3.31e-05	CbGpPWpGaD
Lurasidone—ADRA2C—Metabolism—AKT1—prostate cancer	3.11e-06	3.27e-05	CbGpPWpGaD
Lurasidone—CYP3A4—Metabolism—CAV1—prostate cancer	3.1e-06	3.26e-05	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—KRAS—prostate cancer	3.1e-06	3.25e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Metabolism—PIK3CA—prostate cancer	3.1e-06	3.25e-05	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—TP53—prostate cancer	3.08e-06	3.24e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—MYC—prostate cancer	3.05e-06	3.2e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—TGFB1—prostate cancer	3.04e-06	3.2e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—EGFR—prostate cancer	2.98e-06	3.13e-05	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—IL6—prostate cancer	2.92e-06	3.06e-05	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—PIK3CA—prostate cancer	2.89e-06	3.04e-05	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—PIK3CA—prostate cancer	2.85e-06	2.99e-05	CbGpPWpGaD
Lurasidone—CYP3A4—Metabolism—PIK3CG—prostate cancer	2.82e-06	2.97e-05	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—IL6—prostate cancer	2.82e-06	2.97e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—KRAS—prostate cancer	2.82e-06	2.96e-05	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—TP53—prostate cancer	2.8e-06	2.94e-05	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—TP53—prostate cancer	2.75e-06	2.89e-05	CbGpPWpGaD
Lurasidone—HTR1A—Signaling Pathways—AKT1—prostate cancer	2.69e-06	2.83e-05	CbGpPWpGaD
Lurasidone—CYP3A4—Metabolism—INS—prostate cancer	2.67e-06	2.81e-05	CbGpPWpGaD
Lurasidone—CYP3A4—Metabolism—CREBBP—prostate cancer	2.62e-06	2.75e-05	CbGpPWpGaD
Lurasidone—ADRA2C—Signaling Pathways—AKT1—prostate cancer	2.6e-06	2.74e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—PIK3CA—prostate cancer	2.59e-06	2.72e-05	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—IL6—prostate cancer	2.56e-06	2.69e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Metabolism—AKT1—prostate cancer	2.53e-06	2.66e-05	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—IL6—prostate cancer	2.52e-06	2.65e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—TP53—prostate cancer	2.5e-06	2.63e-05	CbGpPWpGaD
Lurasidone—CYP3A4—Metabolism—PIK3CD—prostate cancer	2.48e-06	2.61e-05	CbGpPWpGaD
Lurasidone—DRD2—Signaling Pathways—AKT1—prostate cancer	2.36e-06	2.48e-05	CbGpPWpGaD
Lurasidone—CYP3A4—Metabolism—NOS3—prostate cancer	2.34e-06	2.46e-05	CbGpPWpGaD
Lurasidone—HTR2A—Signaling Pathways—AKT1—prostate cancer	2.32e-06	2.44e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—IL6—prostate cancer	2.29e-06	2.41e-05	CbGpPWpGaD
Lurasidone—CYP3A4—Metabolism—PIK3CB—prostate cancer	2.16e-06	2.27e-05	CbGpPWpGaD
Lurasidone—CYP3A4—Metabolism—PTGS2—prostate cancer	2.14e-06	2.25e-05	CbGpPWpGaD
Lurasidone—ADRA2A—Signaling Pathways—AKT1—prostate cancer	2.11e-06	2.22e-05	CbGpPWpGaD
Lurasidone—CYP3A4—Metabolism—PTEN—prostate cancer	1.87e-06	1.96e-05	CbGpPWpGaD
Lurasidone—CYP3A4—Metabolism—EP300—prostate cancer	1.78e-06	1.87e-05	CbGpPWpGaD
Lurasidone—CYP3A4—Metabolism—PIK3CA—prostate cancer	1.32e-06	1.39e-05	CbGpPWpGaD
Lurasidone—CYP3A4—Metabolism—AKT1—prostate cancer	1.08e-06	1.13e-05	CbGpPWpGaD
